Indeglitazar

Drug Profile

Indeglitazar

Alternative Names: PLX-204; PPM-204

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Plexxikon
  • Class Carboxylic acids; Indoles; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 04 Apr 2011 Plexxikon has been acquired by Daiichi Sankyo Company
  • 22 Sep 2010 Indeglitazar is available for licensing (\www.plexxikon.com\)
  • 09 Jun 2009 Pharmacodynamics data from a preclinical trial in Diabetes mellitus presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top